These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 8697400)
1. Phase II evaluation of topotecan for pediatric central nervous system tumors. Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923 [TBL] [Abstract][Full Text] [Related]
3. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950 [TBL] [Abstract][Full Text] [Related]
4. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866 [TBL] [Abstract][Full Text] [Related]
5. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738 [TBL] [Abstract][Full Text] [Related]
7. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Friedman HS; Kerby T; Fields S; Zilisch JE; Graden D; McLendon RE; Houghton PJ; Arbuck S; Cokgor I; Friedman AH Cancer; 1999 Mar; 85(5):1160-5. PubMed ID: 10091802 [TBL] [Abstract][Full Text] [Related]
8. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657 [TBL] [Abstract][Full Text] [Related]
9. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806 [TBL] [Abstract][Full Text] [Related]
10. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767 [TBL] [Abstract][Full Text] [Related]
11. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810 [TBL] [Abstract][Full Text] [Related]
12. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572 [TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin. Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584 [TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578 [TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G; J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620 [TBL] [Abstract][Full Text] [Related]
16. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380 [TBL] [Abstract][Full Text] [Related]
17. Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study. Längler A; Christaras A; Abshagen K; Krauth K; Hero B; Berthold F Klin Padiatr; 2002; 214(4):153-6. PubMed ID: 12165894 [TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases. Kocher M; Eich HT; Semrau R; Güner SA; Müller RP Strahlenther Onkol; 2005 Jan; 181(1):20-5. PubMed ID: 15660189 [TBL] [Abstract][Full Text] [Related]
19. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603 [TBL] [Abstract][Full Text] [Related]